Impact of residual inflammation on myocardial recovery and cardiovascular outcome in Takotsubo patients

• DOI: 10.1002/ehf2.12945
• Publication Date: 2020-11-18T23:52:09Z
• Authors: Lucie Lachmet‐The...; Benjamin Marchandot; Kensuke Matsushita; Chisato Sato; Charlotte Dagrenat; Stephane Greciano; Fabien De Poli; Pierre Leddet; Marilou Peillex; Sébastien Hess; Adrien Carmona; Charline Jimenez; Joe Heger; Antje Reydel; Patrick Ohlmann; Laurence Jesel; Olivier Morel
• Keywords: Clinical endpoint

Abstract Aims Recent insights have emphasized the importance of myocardial and systemic inflammation in Takotsubo syndrome (TTS). In a large registry unselected patients, we sought to evaluate whether residual high inflammatory response (RHIR) could impact cardiovascular outcome after TTS. Methods results Patients with TTS were retrospectively included between 2008 2018 three general hospitals. Three hundred eighty‐five patients split into subgroups, according tertiles C‐reactive protein (CRP) levels at discharge (CRP <5.2 mg/L, CRP range 5.2 19 >19 mg/L). The primary endpoint was RHIR, defined as mg/L discharge, on cardiac death or hospitalization for heart failure. Follow up obtained 382 (99%) median 747 days. RHIR more likely history cancer physical trigger. Left ventricular ejection fraction (LVEF) admission comparable groups. By contrast, associated lower LVEF follow (61.7% vs. 60.7% 57.9%; P = 0.004) increased late mortality (0% 0% 10%; 0.001). multivariate Cox regression analysis, an independent predictor failure (hazard ratio: 1.87; 95% confidence interval: 1.08 3.25; 0.025). Conclusions Residual impaired evidenced factor events. All together, these findings underline high‐risk subgroup, target future clinical trials specific therapies attenuate RHIR.